Companion Diagnostic Market Research Report by Test Type (HER2 Testing, PD-1 Testing, EGFR Mutation Testing, ALK Rearrangement Testing, Others), by Products & Services (Assays, Reagents & Kits, Instruments/Systems, Software & Services), by Technology [Pol

The global companion diagnostic market is anticipated to witness significant growth, reaching USD 25,300.58 million by 2035. Registering a CAGR of 12.68% during the 2025–2035 period, this growth is largely attributed to the increasing focus on targeted therapies and improved patient outcomes.

Increasing Disease Incidence Driving Targeted Diagnostics Adoption
The sharp rise in global cancer and chronic disease cases is fueling the expansion of the companion diagnostics market by necessitating more accurate and individualized treatment solutions. As a result, biomarker-driven testing is gaining traction to enhance treatment efficacy and reduce unnecessary interventions.

Market Segmentation Overview
• HER2 Testing – Essential for personalized breast cancer therapy
• PD-1 Testing – Determines suitability for immune checkpoint therapies
• EGFR Mutation Testing – Guides precision treatment in lung cancer
• ALK Rearrangement Testing – Identifies key oncogenic gene alterations
• Others (Test Type) – Includes novel and emerging diagnostic tests
• Assays – Fundamental tools for biomarker identification processes
• Reagents & Kits – Support efficient and reliable diagnostic operations
• Instruments/Systems – Provide technological backbone for diagnostic procedures
• Software & Services – Improve analytics and diagnostic decision-making
• PCR – Offers fast and accurate DNA amplification capabilities
• NGS – Provides extensive genomic insights for precision medicine
• IHC – Evaluates protein expression in clinical samples
• FISH – Detects genetic variations using fluorescent labeling
• Others (Technology) – Represents additional advanced diagnostic methods
• Cancer – Leading indication with high diagnostic demand globally
• Neurological Disorders – Enables improved diagnosis of brain diseases
• Cardiovascular Disorders – Supports targeted cardiovascular disease management
• Infectious Disease – Helps identify pathogens and guide treatments
• Biopharmaceutical and Biotechnology Companies – Lead innovation in precision medicine
• CROs and CDMOs – Enable outsourced development and manufacturing capabilities
• Others (End User) – Comprises hospitals, labs, and academic institutions

Regional Insights Summary
Strong regulatory backing and increasing cancer cases position North America as the leading region in the companion diagnostics market. Europe and Asia Pacific are emerging as high-growth regions fueled by rising disease incidence and evolving healthcare frameworks.

Advancing Precision Oncology with QIAcuityDx
In September 2024, QIAGEN unveiled QIAcuityDx, a next-generation digital PCR platform tailored for clinical oncology and liquid biopsy testing, enabling rapid and accurate molecular analysis. Supported by strong regulatory compliance and strategic pharma collaborations, this launch enhances its ecosystem and drives innovation in companion diagnostics.

Evolving Regulatory and Innovation Landscape
Supportive regulatory developments and growing emphasis on co-development of therapies and diagnostics are accelerating adoption beyond cancer care. This evolving ecosystem is strengthening the role of companion diagnostics in delivering personalized treatment across multiple therapeutic areas.

Key Report Attributes
• Market Size 2035: USD 25,300.58 Million
• CAGR (2025-2035): 12.68%
• Base Year: 2024
• Market Forecast Period: 2025-2035

Industry Segmentations Growth
• By Test Type: HER2 Testing - 10.90%, PD-1 Testing - 12.03%.
• By Products & Ser5vices: Assays - 12.27%, Reagents & Kits - 12.99%.
• By Technology: Polymerase Chain Reaction (PCR) -12.95%, Next-Generation Sequencing (NGS) - 13.91%.
• By Indication: Cancer - 12.67%, Neurological Disorders - 11.93%.
• By End User: Biopharmaceutical and Biotechnology Companies - 12.35%, CROs and CDMOs - 13.91%. Show more